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Abstract Activin A, a member of TGFI8 superfamily has vari- 
ous activities including induction of apoptosis in mammalian cells. 
However, it remains unknown how activin A induces cell death. 
To clarify this, we investigated the expression of BCL-2 and 
BAX, and the effect of BCL-2 overexpression on activin A- 
induced apoptosis in B cell hybridoma cell lines. The activin 
A-sensitive cell lines expressed BAX but not BCL-2 and that 
activin A did not increase BAX levels. Overexpression of human 
BCL-2 suppressed activin A-induced apoptosis in these cells. 
Thus, activin A has been shown to induce apoptosis by a BCL-2- 
inhibitable mechanism without activating BAX. 
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1. Introduction 
Activin A was originally isolated as a factor stimulating se- 
cretion of follicle-stimulating hormone (FSH) from anterior 
pituitary cells [1]. It possesses various in vitro activities uch as 
enhancement of neuronal survival [2], induction of erythroid 
differentiation [3] and mesoderm formation during amphibian 
embryonic development [4,5]. Recently, we reported that ac- 
tivin A induces apoptotic ell death of some myelomas, and that 
TGFfl shows no cytotoxic effect on these cells [6]. Activins bind 
to cell-surface molecules of 50-55 kDa and 70-75 kDa known 
as activin receptors type I (ActR I) [7] and type II (ActR II) [8]. 
These receptors are members of a newly-defined family of 
transmembrane serine/threonine kinase, which includes the daf- 
I gene product of Caenorhabditis elegans and the type II TGFfl 
receptor [9]. Activin A may mediate a variety of activities 
through different combinations of ActR subtypes or isotypes. 
We previously reported that activin A derived from activated 
macrophages induced apoptotic ell death in B lineage cells 
[10], suggesting the possible role of activin A in B cell im- 
munoregulation. Apoptosis is a self-killing mechanism with 
morphological nd biochemical characteristics and contributes 
to the structural reorganization during embryonic develop- 
ment, clonal selection in the immune system and abortion of 
cells with damaged DNA [11]. The BCL-2 product is a 26-kDa 
protein localized to outer-membranes of nuclei, mitochondria 
and endoplasmic reticula [12]. The ability of BCL-2 to enhance 
the survival of hematopoietic cells is related to its ability to 
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block apoptosis caused by growth factor deprivation [13]. How- 
ever, some types of apoptosis cannot be blocked by expression 
of exogenous BCL-2 [14]. Recently, genes related to BCL-2 
have been cloned and form the BCL-2 family [15]. Oltvai et al. 
reported that BAX product, a member of the BCL-2 family, 
antagonizes the anti-apoptotic a tivity of BCL-2 by forming a 
heterodimer with BCL-2 [16]. Failure of BCL-2 to block apop- 
tosis may be explained by involvement ofother members of the 
BCL-2 family in the regulation of apoptosis in certain types of 
cells or apoptotic stimuli. In this study, we investigated the 
mechanism of activin A-induced B cell apoptosis by analyzing 
BCL-2 and BAX expression and the effect of BCL-2 overex- 
pression on activin A-induced B cell death. We show here that 
induction of high levels of human BCL-2 blocks activin A- 
induced apoptosis and that activin A does not enhance xpres- 
sion of BAX. 
2. Materials and methods 
2.1. Cell culture and plasmid 
Establishment and characterization f mouse hybridoma HS-5 and 
HS-7 cell lines were described previously [10]. HS-72 is a subclone of 
HS-7 cell line sensitive toactivin A-induced cell death. Mouse leukemic 
M1 and human monoblastic U937 cell lines were obtained from 
RIKEN Cell Bank and Japanese Cancer Research Resource Bank, 
respectively. HS-5, HS-72 and M 1 cells were cultured in Iscove's mod- 
ified Dulbecco's medium (IMDM; GIBCO Laboratories, Grand Is- 
land, NY) and U937 cells were maintained in RPMI 1640 (GIBCO 
Laboratories), both containing 10% heat-inactivated f tal calf serum 
(FCS), 100 pg/ml streptomycin a d 100 U/ml penicillin. Construction 
of BCL-2 expression plasmid pCAj-bcl-2 and control plasmid pCAj-SV2 
was reported [17]. Cells were transfected with plasmid by electropora- 
tion using a Electroporator II (Invitrogen, San Diego, CA) at 200 V, 
1000 pF and then selected by cultivation with G418 (450/tg/ml). Single- 
cell clones were obtained by limiting dilution. 
2.2. MTT assay 
Ceils seeded at a density of 2 × 105/ml in 96-well plates were incubated 
with IMDM containing 5% FCS and antibiotics in the presence of 
various concentrations of activin A at 37°C and then examined for cell 
viability by colorimetric assay with MTT (3-[4,5-dimethylthiazol2-yl]- 
2,5-diphenyltetrazolium bro ide, Sigma Chemical Co., St. Louis, MO) 
[6]. Absorbance was determined at a wave length of 570 nm with 
background subtraction at 620 nm. 
2.3. Detection of apoptotic cells 
To detect apoptotic nuclei, the cells were suspended in hypotonic 
solution (3.4 mM sodium citrate, 0.1% Triton X-100, 0.1 mM EDTA, 
1 mM Tris), stained with 5/tg/ml of propidium iodide and analyzed by 
a FACScan (Becton Dickinson Immunocytometry Systems, San Jose, 
CA) [18]. In DNA fragmentation assay, the cells (5 × 106) were treated 
by proteinase K at 37°C and cellular DNA was extracted by phenol/ 
chloroform [19], electrophoresed in a2% agarose gel and stained with 
ethidium bromide. 
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2.4. hnmunoblot analysis 
A monoclonal ntibody specific to human BCL-2 (clone 124) was 
purchased from Boehringer Mannheim (Mannheim, Germany). Rabbit 
anti-mouse BCL-2 and anti-mouse BAX sera were raised against syn- 
thetic peptides as described previously [20]. The cells were lysed in 
ice-cold lysis buffer (40 mM Tris-HC1, pH 7.4, 140 mM NaC1, 1% 
NP-40) and 20/.tg of protein extracts were electrophoresed in 12.5% 
SDS-polyacrylamide gels, electroblotted onnitrocellulose filters and 
reacted with primary antibodies. Signals were detected by a ECL detec- 
tion kit (Amersham, Buckinghamshire, UK). 
3. Results 
Expression of endogenous BCL-2 was studied in mouse B 
cell hybridoma cell lines (HS-5, HS-72) susceptible to activin 
A-induced apoptosis. Immunoblot analysis revealed that HS-5 
and HS-72 clones expressed negligible levels of endogenous 
mouse BCL-2 as compared with M1 mouse myeloblastic cell 
line (Fig. 1). To test if activin A-triggered apoptotic process can 
be inhibited by BCL-2, HS-5 and HS-72 cell lines were trans- 
fected with human BCL-2 expression plasmid (pCAj-bcl-2) or 
control plasmid (pCAj-SV2) and stable transfectants were se- 
lected by culturing with G418. Two clones (HS-5B-3, HS-5B-6) 
from HS-5 and one clone (HS-72B-16) from HS-7 were found 
to express high levels of human BCL-2 as compared with U937 
human monoblastic cell line and used for further analyses (Fig. 
1). Control plasmid-transfected HS-5S-2 clone from HS-5 and 
HS-72S-4 clone from HS-72 were used as controls. 
The cytotoxic effect of activin A was examined in the control 
plasmid-transfected clones (HS-5S-2, HS-72S-4) and BCL-2 ex- 
pressing clones (HS-5B-3, HS-5B-6, HS-72B-16) by MTT 
assay. As shown in Fig. 2, control clones (HS-5S-2, HS-72S-4) 
showed cytotoxic response to activin A in a dose-dependent 
manner. Activin A-sensitivities of control clones were essen- 
tially the same as those of parental cell lines (data not shown). 
BCL-2 expressing clones (HS-5B-3, HS-5B-6, HS-72B-16) also 
showed cytotoxic response to activin A, but were less sensitive 
than the control clones. As demonstrated in Fig. 3, cultivation 
of HS-5S-2 and HS-72S-4 clones with activin A increased the 
population of nuclei with reduced DNA content representing 
apoptotic nuclei. HS-5B-3 and HS-72B-16 clones showed a 
slight increase in population of apoptotic nuclei. After being 
cultured without activin A, these clones showed less than 6% 
in population of nuclei with reduced DNA content. Gel electro- 
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Fig. I. BCL-2 expression i parental and transfected HS-5 and HS-72 
clones. Mouse endogenous BCL-2 (upper panel) and human exogenous 
BCL-2 (lower panel) expression was studied by immunoblot analysis 
as described insection 2. M1 cells and U937 cells were used as positive 
controls to detect mouse BCL-2 and human BCL-2, respectively. 
mBCL-2, mouse BCL-2; hBCL-2, human BCL-2. 
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Fig. 2. BCL-2 suppresses activin A-cytotoxicity inhybridoma cell ines. 
Cells were cultured in the presence ofvarious concentrations of activin 
A for 48 h and then the MTT assay was performed. E3, HS-5S-2; B, 
HS-5B-3; , ,  HS-5B-6; o, HS-72S-4; e, HS-72B-16. 
phoresis of cellular DNA showed that fragmented DNA was 
much less in activin A-treated HS-5B-3 and HS-72B-16 clones 
than in HS-5S-2 and HS-72S-4 clones exposed to activin A (Fig. 
4). Thus, expression of BCL-2 was shown to inhibit activin 
A-induced apoptosis n mouse B cell hybridoma cells. We tested 
if activin A-induced apoptosis was mediated by increasing level 
of BAX. The parental HS-5 and the transfected clones were 
cultured with activin A for 12 or 24 h and analyzed for BAX 
expression by the immunoblot analysis. As shown in Fig. 5, 
overexpression f BCL-2 did not enhance BAX expression i  
HS-5 cell line. Exposure of the parental and transfected HS-5 
clones to activin A did not increase BAX levels at least for 24 
h, or even slightly decreased its levels. 
4. Discussion 
We showed that mouse B cell hybridoma cell lines sensitive 
to activin A-induced cell death expressed undetectable levels of 
BCL-2 and that overexpression of exogenous BCL-2 sup- 
pressed the cell-killing effect of activin A. These results sug- 
gested that high sensitivity of hybridoma cell lines to activin 
A-mediated apoptosis might be attributed to low levels of en- 
dogenous BCL-2. Inhibition of activin A-induced apoptosis by 
BCL-2 was consistent with the idea that most cases of apopto- 
sis, if not all, are mediated by a common or similar process 
involving members of the BCL-2 family [13,15]. p53-induced 
apoptosis was reported to be caused by suppression of BCL-2 
and activation of BAX [21,22]. However, activin A did not 
enhance BAX expression in the hybridoma cell lines in the 
present study. Similar observation was made in M1 mouse 
myeloblastic cell line stimulated by TGFfl to undergo apoptosis 
[21]. Other apoptosis-stimulating genes uch as BCL-Xs, BAD 
and BAK [15,23 25] might be involved in the induction of 
apoptosis by the TGFfl superfamily. 
Apoptosis is essential in normal development and regulation 
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Fig. 3. Analysis of DNA content in transfected hybridoma clones treated with activin A. Transfectants of hybridoma cell lines were cultured with 
(--) or without (---) activin A (100 ng/ml) for 28 h, stained with propidium iodide and analyzed by flow cytometry. The percentages ofhypodiploid 
nuclei in activn A-treated cells are indicated. Panel A, HS-5S-2; Panel B, HS-5B-3; Panel C, HS-72S-4; Panel D, 
HS-72B-16, 
of the immune system and hematopoiesis [26]. A large amount 
of information has been accumulated during the last few years 
contributing to our knowledge of the principles of apoptosis. 
For the process of elimination of self-reactive B cells, it is likely 
that induction of tolerance involves apoptosis as a part of a 
parallel process of negative selection [27]. We reported previ- 
ously that a factor produced by the mouse macrophage c ll line 
P388D~ cells shows a profound suppressive effect on in vitro 
proliferation of B lineage cells. In the course of the study, this 
negative growth effect was at least in part caused by induction 
of apoptosis. Peptide analysis revealed that the N-terminal 
amino acid sequence of the factor was identical to that of 
activin A [10]. Thus, it is likely that activin A may participate 
in B cell differentiation and immunoregulation through 
crosstalk between macrophages and B cells at a certain differen- 
tiation stage. Further studies are needed to elucidate the precise 
interaction between B lineage cells and macrophages through 
activin A-mediated apoptosis. 
It is well-known that activins transduce their effects through 
binding to ActR I and ActR II. Attisane et al. reported that 
ActR I is transmembrane protein kinases that associate with 
ActR II to generate derivative heterometric serine/threonine 
kinase complexes of differential signaling capacities [28]. We 
showed previously that activin A-induced B cell apoptosis was 
suppressed by an inhibitor of protein kinases, suggesting that 
the apoptotic signals from ActR may be mediated by protein 
kinase and its target protein(s) [10]. Further work is in progress 
to confirm the identity of the kinase and intracellular signal for 
B cell death after binding of activin A to the complex of ActR 
I and ActR II. 
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